Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach

Current Diabetes Reports
Josephine L HarringtonDarren K McGuire

Abstract

With recent cardiovascular outcome trial (CVOT) results for antihyperglycemic medications, the treatment algorithm for patients with type 2 diabetes (T2DM) and atherosclerotic vascular disease (ASCVD) requires revision. All completed CVOTs have demonstrated CV safety of the tested medications, with some trials demonstrating CV efficacy. While metformin remains the first-line recommended medication for T2DM, 18-37% of the patients enrolled in the completed CVOTs were not treated with metformin, providing substantial power to assess CV outcomes independent of metformin. The safety and tolerability of metformin are indisputable, but there are no robust data proving its efficacy for either macro or microvascular disease outcomes. We should reconsider the primacy of metformin in the management of T2DM in patients with ASCVD. This article will review the evidence for CV effects of antihyperglycemic agents (AHAs), and propose an evidence-based treatment algorithm for patients with T2DM and ASCVD.

References

May 26, 2001·Diabetes Care·J L ChiassonUNKNOWN Miglitol Canadian University Investigator Group
Mar 5, 2002·Diabetes Care·Alain G BertoniFrederick L Brancati
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol
Jan 24, 2007·Lancet·Lars RydénKarl Swedberg
Feb 3, 2007·The New England Journal of Medicine·David M Nathan
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Nov 29, 2007·Diabetes Care·Silvio E InzucchiDarren K McGuire
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Mar 1, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Dec 20, 2008·Anesthesia and Analgesia·Kelley Teed Watson, Paul G Barash
Jul 1, 2009·Current Cardiology Reports·M Odette Gore, Darren K McGuire
Nov 17, 2009·Diabetes Research and Clinical Practice·R K SimmonsS J Griffin
May 28, 2011·Diabetes Care·Kasia J LipskaSilvio E Inzucchi
May 12, 2012·Endocrinology and Metabolism Clinics of North America·Anthony L McCall
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Jan 8, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Thomas ForstAxel Haupt
Apr 19, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Dec 24, 2014·JAMA : the Journal of the American Medical Association·Silvio E InzucchiDarren K McGuire
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Nov 10, 2015·British Journal of Clinical Pharmacology·Wendy Klein-SchwartzGeoffrey K Isbister
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jan 10, 2016·BMJ : British Medical Journal·Rémy BoussageonCatherine Cornu

❮ Previous
Next ❯

Citations

Oct 2, 2019·Diabetology & Metabolic Syndrome·Alaaeldin BashierRobert Chilton
Dec 12, 2019·Herz·Franziska Mühleck, Ulrich Laufs
Oct 13, 2020·Frontiers in Physiology·Mario SchubertKaomei Guan
Dec 3, 2020·Pharmaceuticals·Ehtasham AhmadMelanie J Davies
Jan 26, 2021·Therapeutic Advances in Endocrinology and Metabolism·Chelsea BakerNeda Rasouli
Jun 17, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·David J T CampbellEldon Spackman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

© 2022 Meta ULC. All rights reserved